19 May 2021 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Appointment of Non-Executive Director
Alderley Park, 19 May 2021 Redx Pharma (AIM:REDX), the drug discovery and development company focused on oncology and fibrosis, is pleased to announce the appointment of Natalie Berner as a Non-Executive Director with effect from 19 May 2021. Natalie will represent RM Special Holdings 3 LLP, an affiliate of Redmile Group, LLC, a San Francisco based investment firm that focuses on the health care sector ("Redmile"), on the Board of Directors.
Natalie brings extensive experience in the healthcare sector to the Board. She is a Managing Director focusing on Therapeutics at Redmile, which she joined in 2016. Prior to Redmile, Natalie was a Research Associate at the New York University School of Medicine. Natalie received a BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University.
Iain Ross, Chairman of the Board of Redx commented: "We are delighted to welcome Natalie onto the Redx Board to represent Redmile, one of the Company's key investors who have been instrumental in helping us to raise the funds to successfully execute on our business plans. The Board and I look forward to working with Natalie to ensure that we continue to grow Redx into a successful biotech company focused on the treatment of cancer and fibrotic disease."
Following Natalie's appointment, the board will be comprised of seven directors, four of whom including the Chairman are Independent Non-executive Directors (Iain Ross, Peter Presland, Dr Bernard Kirschbaum and Sarah Gordon Wild), two shareholder representative non-executive Directors (Natalie Berner and Dr Thomas Burt) and Lisa Anson as Chief Executive.
Additional information:
The following information is being disclosed pursuant to Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies:
Full name and age: Natalie Brittenham Berner, aged 30
Ms. Berner does not hold any shares in the Company
Ms. Berner is not currently a director of any company and has not been a director of any company in the past five years
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Chairman Lisa Anson, Chief Executive | |
SPARK Advisory Partners Limited (Nominated Advisor) | T: +44 20 3368 3550 |
Matt Davis/Adam Dawes | |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ David Wilson | |
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 20 7886 2500 |
Rupert Dearden/Freddy Crossley/Emma Earl | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin |
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in mid-2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).